This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Cerner (CERN) Up 6.8% Since Last Earnings Report?
by Zacks Equity Research
Cerner (CERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Medical Info System Stocks to Bank on Despite Decline in COVID-19 Cases
by Urmimala Biswas
The Zacks Medical Info Systems industry is gaining from growing demand for digital healthcare support. However, drop in COVID-19 cases might disrupt this uptrend. Industry players CPSI, CNTG and CERN are set to gain the most.
Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Cerner's (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in gross margin.
Cerner (CERN) Beats Q1 Earnings Estimates
by Zacks Equity Research
Cerner (CERN) delivered earnings and revenue surprises of 2.70% and -0.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed recovery in rapid immunoassay revenues during Q1.
Should You Buy Cerner (CERN) Ahead of Earnings?
by Aditi Saraogi
Cerner (CERN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cerner (CERN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) first-quarter results are likely to reflect gains from strategic deals.
Cerner (CERN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cerner (CERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allscripts' (MDRX) Sunrise Platform Picked by Mercy Iowa City
by Zacks Equity Research
Allscripts' (MDRX) Sunrise platform gets selected by Mercy Iowa City, thereby enabling the former to help in delivering better patient outcomes and accelerating the future of healthcare.
Cerner (CERN) Down 6.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cerner (CERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cerner (CERN) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Cerner's (CERN) fourth-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in gross margin.
Cerner (CERN) Q4 Earnings Match Estimates
by Zacks Equity Research
Cerner (CERN) delivered earnings and revenue surprises of 0.00% and 0.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Cerner (CERN) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) fourth-quarter results are likely to reflect gains from strategic deals.
Cerner (CERN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cerner (CERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Top Medical Info Systems Stocks to Beat COVID-19 Resurgence Crisis
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Information industry. OMCL, NXGN and NH are well positioned to gain.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, intense competition remains a woe.
Cerner (CERN) to Buy Kantar Health to Enhance Clinical Research
by Zacks Equity Research
Cerner (CERN) agrees to acquire Kantar Health to drive safety and efficiency of clinical research across life sciences, pharmaceuticals and health care.
Cerner's (CERN) Simplified Digital Tools to Aid Health Systems
by Zacks Equity Research
Cerner (CERN) offers centralized digital ordering and monitoring for clients in order to help health systems.
Cerner's (CERN) Deal to Make Clinical Trials More Accessible
by Zacks Equity Research
Cerner (CERN) inks deal with Elligo Health Research to make clinical trials more accessible, while minimizing costs.
Cerner (CERN) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Cerner's (CERN) third-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in margins.
Cerner (CERN) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Cerner (CERN) delivered earnings and revenue surprises of 1.41% and -0.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Q3 Earnings on Oct 28: BSX, CERN & More
by Urmimala Biswas
In Q3, Medical Product stocks are expected to have gained from gradual lifting of restrictions in many states and regions. However, international sales might have been dampened.
CPSI vs. CERN: Which Stock Is the Better Value Option?
by Zacks Equity Research
CPSI vs. CERN: Which Stock Is the Better Value Option?
Cerner (CERN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.
Cerner (CERN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cerner (CERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.